| Literature DB >> 29441152 |
Mayaris Zepeda Méndez1, Mirjam J Nijdam1,2, F Jackie June Ter Heide1, Niels van der Aa1, Miranda Olff2,3.
Abstract
Background: Trauma-focused psychotherapies for posttraumatic stress disorder (PTSD) have been demonstrated to be efficacious, but also have considerable non-response and dropout rates. Intensive treatment may lead to faster symptom reduction, which may contribute to treatment motivation and thereby to reduction of dropout. Objective: The aim of the current study was to investigate the feasibility and preliminary effectiveness of an intensive five-day inpatient treatment with Eye Movement Desensitization and Reprocessing (EMDR) and trauma-informed yoga for patients with PTSD. Method: A non-controlled pilot study with 12 adult patients with PTSD was conducted. At baseline the PTSD diagnosis was assessed with the Clinician-Administered PTSD Scale (CAPS-5) and comorbid disorders with the Mini International Neuropsychiatric Interview (MINI). Primary outcome was self-reported PTSD symptom severity (PTSD Check List for DSM-5; PCL-5) measured at the beginning of day 1 (T1), at the end of day 5 (T2) and at follow-up on day 21 (T3). Reliable change indexes (RCI) and clinically significant changes were calculated.Entities:
Keywords: Posttraumatic stress disorder; eye movement desensitization and reprocessing; feasibility; intensive treatment; preliminary effect; trauma-focused psychotherapy; yoga; • This pilot study investigated the potential benefits of a five-day inpatient treatment programme with EMDR and trauma-informed yoga for patients with PTSD. • After two weeks, nine out of 12 patients reported a reliable change in self-reported PTSD symptoms. • Although further research is needed to properly investigate the effects, the treatment programme was promising in showing a reduction in symptoms in a short time frame.
Year: 2018 PMID: 29441152 PMCID: PMC5804727 DOI: 10.1080/20008198.2018.1425575
Source DB: PubMed Journal: Eur J Psychotraumatol ISSN: 2000-8066
Baseline demographic and clinical characteristics of intent-to-treat sample (N = 12).
| Male | 9 (75.0) | ||
| Civil status | Single | 2 (16.7) | |
| Married/partnership | 3 (25.0) | ||
| Married/partnership with children | 7 (58.3) | ||
| Educational levela | Low | 3 (25.0) | |
| Middle | 5 (41.7) | ||
| High | 4 (33.3) | ||
| Trauma type | Veteran | 6 (50.0) | |
| Police | 4 (33.3) | ||
| Both childhood trauma and adult trauma | 1 (8.3) | ||
| Asylum seeker | 1 (8.3) | ||
| Exposed to childhood abuse | 6 (50.0) | ||
| No previous trauma treatment | 7 (58.3) | ||
| Mini International Neuropsychiatric Interview | Major depressive disorder | 7 (58.3) | |
| ( | Panic disorder with agoraphobia | 3 (25.0) | |
| Obsessive compulsive disorder | 2 (16.7) | ||
| Alcohol dependency | 2 (16.7) | ||
| Age | 44.20 (11.10) | ||
| Years after index trauma | 18.00 (13.74) | ||
| Months of previous treatment | 20.83 (27.95) | ||
| Baseline CAPS total scoreb | 40.75 (7.66) | ||
| Baseline PCL-5 total score | 47.00 (9.96) | ||
| Baseline BSI total score | 1.77 (0.65) |
aLow: completed elementary school or lower vocational education.
Middle: completed high school or middle level vocational education.
High: completed high level vocational education, pre-university, college or university degree.
bOne patient fulfilled the criteria of the dissociative subtype of PTSD.
PCL-5 scores of total group (N = 12) and in categories of recovered, improved and unchanged.
| T1 Mean ( | T2 Mean ( | T3 Mean ( | |
|---|---|---|---|
| PCL-5 total | 52.67 (14.34) | 42.67 (17.20) | 36.25 (20.95) |
| Recovered ( | 49.50 (0.71) | 37.00 (25.46) | 20.00 (9.90) |
| Improved ( | 50.57 (17.75) | 40.29 (17.24) | 31.86 (20.65) |
| Unchanged ( | 59.66 (9.29) | 52.00 (15.10) | 57.33 (9.29) |
T1 = day 1; T2 = day 5; T3 = day 21; PCL-5 total score: recovered = no probable diagnosis of PTSD and RC ≤ −1.96; improved = probable diagnosis of PTSD and RC ≤ −1.96; unchanged = probable PTSD diagnosis and RC > −1.96 or <+1.96.
Figure 1.Mean total PCL-5 scores on T1, T2 and T3 in groups of recovered (patient number: 4,7), improved (patient number: 2,11,12,6,1,9,10) and unchanged (patient number: 8,3,5) patients.
Treatment outcome and reliable change indexes on PCL-5 scores per patient from T1 to T2 and from T1 to T3.
| Patient number | PCL total | RCI T1–T2 | PCL total | RCI T1–T3 |
|---|---|---|---|---|
| 4 | 1 | −5.72 | 1 | −6.86 |
| 7 | 3 | 0.95 | 1 | −4.38 |
| 2 | 3 | 0.38 | 2 | −4.95 |
| 11 | 3 | 0.57 | 2 | −2.86 |
| 12 | 1 | −7.24 | 2 | −6.48 |
| 6 | 3 | −0.76 | 2 | −3.24 |
| 1 | 3 | −1.52 | 2 | −2.86 |
| 9 | 3 | −1.91 | 2 | −2.48 |
| 10 | 2 | −3.24 | 2 | −2.10 |
| 8 | 3 | −1.91 | 3 | −0.76 |
| 3 | 1 | −2.48 | 3 | −0.38 |
| 5 | 3 | - | 3 | −0.19 |
T1–T2 = difference between day 5 and day 1; T1–T3 = difference between day 21 and day 1; PCL-5 total score: 1 = recovered (no probable diagnosis of PTSD and RC ≤ −1.96); 2 = improved (probable diagnosis of PTSD and RC ≤ −1.96); 3 = unchanged (probable PTSD diagnosis and RC > −1.96 or < +1.96).
Tolerability of treatment on visual analogue scale (0–10).
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | |
|---|---|---|---|---|---|
| Session 1 | 4.64 (3.14) | 4.58 (3.19) | 4.79 (3.94) | 5.16 (3.32) | |
| Session 2 | 4.99 (3.09) | 5.63 (3.10) | 5.62 (3.76) | 3.83 (3.16) | 2.66 (2.30) |